POPeters Oluwale Oladosu

Peters Oluwale Oladosu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Peters Oluwale Oladosu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Time-kill kinetics antibacterial activity of ethyl-acetate extract of Bacillus subtilis subsp. subtilis 168.

    by Olasinbo Olumuyiwa Balogun, Sylvanus Chukwudi Ugoh, Olabisi Peter Abioye, Peters Oluwale Oladosu

    Background: The rise in antibiotic-resistant pathogens underscores the urgent need to fortify the existing weak antimicrobial agents. Novel antimicrobials are products of microbes, as two-thirds of the currently available antibiotics are sourced from them. Understanding the killing rate of the potential antibiotic-producing microbe is essential during the development of antimicrobials. Our preliminary investigation identified a potential antibiotic-producing Bacillus subtilis subsp. subtilis168. Method: In this study, we investigated the inhibitory activity and time-kill kinetics of the extract of Bacillus subtilis subsp. subtilis 168 against some selected pathogenic strains. Broth microdilution and time-kill assays were used to evaluate the antibacterial activity of the extract. Data analysis was performed with the Kruska-Wallis H test using the statistical software Stata 16. Results:The extract showed antibacterial activity against Staphylococcus aureus (ATCC 25923) (MIC = 28.70 mg/mL), Escherichia coli (ATCC 25922) (MIC = 28.70 mg/mL), Pseudomonas aeruginosa(ATCC 27853) (MIC = 28.70 mg/mL) and K. pneuminiae (MIC = 14.35 mg/mL). At 0.5 × MIC, the extract was bacteriostatic against all the test bacteria for the 24-hour incubation period. At the 1 x MIC (28.70 mg/mL), the extract achieved bactericidal endpoints (≥99.9% killing) of 3.87 Log10 CFU/mL reduction of S. aureus (ATCC 25923) at 6 h incubation, 6.81 Log10 CFU/mL reduction of E. coli (ATCC 25922) at 6 h (1 x MIC: 28.70 mg/mL), 6.87 Log10 CFU/mL reduction of P. aeruginosa (ATCC 27853) at 8 h (1 x MIC: 28.70 mg/mL), and 6.90 Log10 CFU/mL reduction at 8 h incubation of K. pneumoniae (1 x MIC: 14.35 mg/mL). At 2 x MIC, the extract showed bactericidal endpoints of at least 3 Log10 CFU/mL reduction of all the test strains at lower exposure times. The killing kinetics of the extract against each test strain were statistically significant (P ≤ 0.05) at 0.5 x MIC, 1 x MIC, and 2 x MIC. Conclusion: The killing kinetics of the extract demonstrated both time- and concentration-dependent bactericidal activity against the selected panel of pathogenic strains, achieving a minimum three-log reduction at 1 × MIC and 2 × MIC within 2-8 h exposure. These findings suggest the promising therapeutic potential of the extract.


  • Impact of Diameter of Inhibition in Crowded Plates on the in vitro Inhibitory Strength of Potential Antibiotic-Producing Bacteria Isolated from Some Natural Habitats

    by Olasinbo Olumuyiwa Balogun, Sylvanus Chukwudi Ugoh, Olabisi Peter Abioye, Peters Oluwale Oladosu

    Antimicrobial resistance is a global problem, and efforts to replace failing antibiotics are crucial. We investigated the impact of the diameter of inhibition (mm) in crowded plates of potential antibiotic-producing bacteria on their in-vitro inhibitory strength. Our previous research identified 12 potential antibiotic-producing bacteria from natural habitats and obtained their diameters of inhibition in preliminary crowded plates. The potential candidates were further challenged with some pathogenic microbes by the Agar-well diffusion technique to test their strength. The results showed that the diameter of inhibition of the potential antibiotic-producing isolates obtained at the crowded plate technique level was not a predictor of the potency of potential antibiotic-producing bacteria (rs = 0.52, P = 0.08). In summary, the selection of potent candidate microbes for the development of new antimicrobial compounds against multidrug-resistant pathogens cannot be determined based on the diameter of inhibition in a preliminary investigation using the crowded plate technique. Further studies involving complementary techniques are necessary to determine the best potential candidate organisms for the development of novel antimicrobial compounds.


  • Open Access

    Comparative Study on Effectiveness of Commercial Antibiotic Discs in Federal Capital Territory (FCT), Nigeria

    by Mercy I. Aboh, Yakubu Ya’aba, Shehu B. Mohammed, Peters O. Oladosu

    Clinically, antimicrobial susceptibility testing results provide guidance in the choice of antimicrobial agents in patient care. The accuracy of results from antimicrobial susceptibility testing can be affected by multiple factors including the media, antimicrobial discs or preparations, inoculum’s size, plate reading and incubation conditions. Misleading results from antimicrobial susceptibility test leads to the indiscriminate and irrational use of antibiotics and have impacted grossly to the global challenge of antimicrobial resistance. The objectives of this study were to compare the efficacy of different brands of locally and foreign manufactured multi-antibiotic discs on bacteria and assess any significant variation. Two brands each of locally and foreign manufactured multi-antibiotic discs were purchased from retail stores within the FCT. The antibacterial susceptibility of Staphylococcus aureus ATCC 25923, Salmonella typhi ATCC 9150, Klebsiella pneumonia, Pseudomonas aeruginosa, Bacillus subtilis, Escherichia coli ATCC 25922 and Streptococcus pyogenes were carried out using agar diffusion method. There were differences between the diameter zones of inhibition produced by the local brands and the foreign brands of antibiotic discs. Amoxicillin/clavulanic acid (30 µg) disc produced the highest variation within the four brands with zones of inhibition range 12.0 – 20.0 mm against the test organisms. There is need for regulatory bodies like NAFDAC and SON to routinely validate and assess the qualities of these products in the market.